This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: May 7th, 2008 - May 7th, 2009

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This educational publication is designed for physicians, nurses, and pharmacists who wish to enhance their knowledge concerning the management of patients with multiple myeloma and renal dysfunction.

Learning Objectives
At the completion of this activity participants should be able to:

• Describe the prevalence of renal insufficiency among patients with multiple myeloma (MM)
• Recognize the special challenges in pharmacologic treatment of the many patients with MM who also have renal insufficiency, especially those requiring dialysis
• Discuss the results of studies showing treatments that are active and safe in MM patients with renal impairment, including those with advanced renal failure requiring dialysis

Disclosure Statement
In direct response to the September 2004 ACCME Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to the date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during the CME/CE activity. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceutical, medical equipment, prostheses, etc will be included in their presentation.

Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

Beth Chen, PharmD, BCOP has nothing to disclose.

Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.

*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.


*Content will include non-FDA-approved uses.

Disclaimer
The contents of some CME activities may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.